Vaxchora: A Single-Dose Oral Cholera Vaccine

Annals of Pharmacotherapy

Volumn 51, Issue 7, 2017, Pages 584-589

  Cabrera, Adriana ^a   Lepage, Jayne E ^a   Sullivan, Karyn M ^a   Seed, Sheila M ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

CVD 103 HgR vaccine; oral cholera vaccine; Vaxchora; Vibrio cholerae

Indexed keywords

CHOLERA VACCINE; VAXCHORA;

ABDOMINAL PAIN; CHOLERA; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG COST; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; MULTICENTER STUDY (TOPIC); PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; TREATMENT CONTRAINDICATION; VACCINATION; VACCINE IMMUNOGENICITY; ADULT; CHILD; ISOLATION AND PURIFICATION; ORAL DRUG ADMINISTRATION; VIBRIO CHOLERAE;

ADMINISTRATION, ORAL; ADULT; CHILD; CHOLERA; CHOLERA VACCINES; HUMANS; VACCINATION; VIBRIO CHOLERAE;

EID: 85020843332     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028017698162     Document Type: Review

References (21)

1. Centers for Disease Control and Prevention. Cholera: Vibrio cholerae infection. General information. http://www.cdc.gov/cholera/general/index.html. Updated November 9, 2016. Accessed December 12, 2016.
2. World Health Organization. Cholera: fact sheet. http://www.who.int/mediacentre/factsheets/fs107/en/. Accessed December 9, 2016.
3. Centers for Disease Control and Prevention. Cholera: Vibrio cholerae infection. Sources of infection and risk factors. https://www.cdc.gov/cholera/infection-sources.html. Updated November 9, 2016. Accessed December 12, 2016.
4. Wong KK., Cholera vaccine update and proposed recommendations. Paper presented at: Advisory Committee on Immunization Practices Meeting; June 22, 2016; Atlanta, GA. http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2016-06/cholera-02-wong.pdf. Accessed August 3, 2016.
5. Centers for Disease Control and Prevention. National enteric disease surveillance: COVIS annual summary, 2014. https://www.cdc.gov/nationalsurveillance/pdfs/covis-annual-summary-2014-508c.pdf. Accessed December 9, 2016.
6. Chen WH, Greenberg RN, Pasetti MF. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks. Clin Vaccine Immunol. 2014;21:66-73. doi:10.1128/CVI.00601-13.
7. Food and Drug Administration. FDA approves vaccine to prevent cholera for travelers. FDA News Release June 10, 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm506305.htm. Accessed September 1, 2016.
8. Herzog C., Successful comeback of the single-dose live oral cholera vaccine CVD 103-HgR. Travel Med Infect Dis. 2016;14:373-377. doi:10.1016/j.tmaid.2016.07.003.
9. Vaxchora (lyophilized CVD 103-HgR oral cholera vaccine) [online package insert]. Redwood City, CA: PaxVax, Inc; 2016. https://www.paxvaxconnect.com/PDF/Vaxchora_Prescribing_Information.pdf. Accessed December 12, 2016.
10. Lagos R, San Martin O, Wasserman SS., Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers. Pediatr Infect Dis J. 1999;18:624-630.
11. Kotloff KL, Waserman SS, O’Donnell S, Losonsky GA, Cryz SJ, Levin MM., Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo controlled, double-blind crossover trial. Infect Immun. 1992;60:4430-4432.
12. Tacket CO, Cohen MB, Wasserman SS., Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect Immun. 1999;67:6341-6345.
13. Suharyono Simanjuntak C, Witham N. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet. 1992;340:689-694.
14. Chen WH, Cohen MB, Kirkpatrick BD. Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor. Clin Infect Dis. 2016;62:1329-1335. doi:10.1093/cid/ciw145.
15. PaxVax Inc. A phase 3 lot to lot consistency study of live oral cholera vaccine, PXVX200 in healthy adults. https://clinicaltrials.gov/ct2/show/NCT02094586?term=pxvx200&rank=2. Updated July 15, 2015. Accessed August 8, 2016.
16. PaxVax Inc. A study of live oral cholera vaccine, PXVX200 in healthy older adults. https://clinicaltrials.gov/ct2/show/NCT02100631?term=pxvx200&rank=1. Updated July 15, 2015. Accessed August 8, 2016.
17. University of Maryland. PXVX0200 (CVD 103-HgR) vs Shanchol in Mali. https://clinicaltrials.gov/ct2/show/NCT02145377?term=NCT02145377&rank=1. Updated April 19, 2016. Accessed August 24, 2016.
18. Gotuzzo E, Butron B, Seas C. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun.1993;61:3994-3997.
19. Levine MM., Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol. 2010;8:129. doi:10.1186/1741-7007-8-129.
20. Suharyono Simanjuntak C, Witham N. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5–9-year-old Indonesian children. Lancet. 1992;340:689-694.
21. Kollaritsch H, Que JU, Kunz C, Wiedermann G, Herzog C, Cryz SJ, Jr. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. J Infect Dis. 1997;175:871-875.